BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26661278)

  • 1. Alcohol Regulates Genes that Are Associated with Response to Endocrine Therapy and Attenuates the Actions of Tamoxifen in Breast Cancer Cells.
    Candelaria NR; Weldon R; Muthusamy S; Nguyen-Vu T; Addanki S; Yoffou PH; Karaboga H; Blessing AM; Bollu LR; Miranda RC; Lin CY
    PLoS One; 2015; 10(12):e0145061. PubMed ID: 26661278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
    Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
    PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells.
    Yang Z; Barnes CJ; Kumar R
    Clin Cancer Res; 2004 Jun; 10(11):3621-8. PubMed ID: 15173068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of RBCK1 as a novel regulator of FKBPL: implications for tumor growth and response to tamoxifen.
    Donley C; McClelland K; McKeen HD; Nelson L; Yakkundi A; Jithesh PV; Burrows J; McClements L; Valentine A; Prise KM; McCarthy HO; Robson T
    Oncogene; 2014 Jun; 33(26):3441-50. PubMed ID: 23912458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer.
    Tian X; Zhang Z
    IUBMB Life; 2018 Jan; 70(1):71-80. PubMed ID: 29247596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A.
    Ikeda K; Horie-Inoue K; Ueno T; Suzuki T; Sato W; Shigekawa T; Osaki A; Saeki T; Berezikov E; Mano H; Inoue S
    Sci Rep; 2015 Aug; 5():13170. PubMed ID: 26255816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation.
    Schlange T; Matsuda Y; Lienhard S; Huber A; Hynes NE
    Breast Cancer Res; 2007; 9(5):R63. PubMed ID: 17897439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation function-1 domain of estrogen receptor regulates the agonistic and antagonistic actions of tamoxifen.
    Glaros S; Atanaskova N; Zhao C; Skafar DF; Reddy KB
    Mol Endocrinol; 2006 May; 20(5):996-1008. PubMed ID: 16455819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-574-3p, identified by microRNA library-based functional screening, modulates tamoxifen response in breast cancer.
    Ujihira T; Ikeda K; Suzuki T; Yamaga R; Sato W; Horie-Inoue K; Shigekawa T; Osaki A; Saeki T; Okamoto K; Takeda S; Inoue S
    Sci Rep; 2015 Jan; 5():7641. PubMed ID: 25560734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
    Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MICAL-L2, as an estrogen-responsive gene, is involved in ER-positive breast cancer cell progression and tamoxifen sensitivity via the AKT/mTOR pathway.
    Wen P; Li J; Wen Z; Guo X; Ma G; Hu S; Xu J; Zhao H; Li R; Liu Y; Wang Y; Gao J
    Biochem Pharmacol; 2024 Jul; 225():116256. PubMed ID: 38729448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of FGFR3 actions in endocrine resistant breast cancer.
    Tomlinson DC; Knowles MA; Speirs V
    Int J Cancer; 2012 Jun; 130(12):2857-66. PubMed ID: 21792889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aromatase and breast cancer.
    Brodie A; Sabnis G; Jelovac D
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.
    Ellis MJ; Coop A; Singh B; Tao Y; Llombart-Cussac A; Jänicke F; Mauriac L; Quebe-Fehling E; Chaudri-Ross HA; Evans DB; Miller WR
    Cancer Res; 2003 Oct; 63(19):6523-31. PubMed ID: 14559846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene regulation in an MCF-7 cell line that naturally expresses an estrogen receptor unable to directly bind DNA.
    Pentecost BT; Bradley LM; Gierthy JF; Ding Y; Fasco MJ
    Mol Cell Endocrinol; 2005 Jun; 238(1-2):9-25. PubMed ID: 15913882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear factor-ĸB plays a critical role in both intrinsic and acquired resistance against endocrine therapy in human breast cancer cells.
    Oida K; Matsuda A; Jung K; Xia Y; Jang H; Amagai Y; Ahn G; Nishikawa S; Ishizaka S; Jensen-Jarolim E; Matsuda H; Tanaka A
    Sci Rep; 2014 Feb; 4():4057. PubMed ID: 24531845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.
    Giannoudis A; Malki MI; Rudraraju B; Mohhamed H; Menon S; Liloglou T; Ali S; Carroll JS; Palmieri C
    Breast Cancer Res; 2020 Nov; 22(1):126. PubMed ID: 33198803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.